Skip to main content

Trudy G Oliver

Professor of Pharmacology and Cancer Biology
Pharmacology & Cancer Biology
Campus Box 3813, Durham, NC 27708
308 Research Drive, LSRC C138B, Durham, NC 27708

Overview


The Oliver Lab is focused on understanding the biology of under-studied subtypes of lung cancer, specifically squamous and small cell lung cancer (SCLC). We investigate mechanisms of tumor cell fate, lineage plasticity, and drug resistance to uncover vulnerabilities that can be therapeutically targeted. We capitalize on state-of-the-art mouse and patient-derived models to identify and test novel treatment strategies, with the goal of translating these findings to the clinic.

Current Appointments & Affiliations


Professor of Pharmacology and Cancer Biology · 2023 - Present Pharmacology & Cancer Biology, Basic Science Departments
Member of the Duke Cancer Institute · 2022 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published January 15, 2026
Trudy G. Oliver, Duke University - Small Cell Lung Cancer
Published December 8, 2025
Dr. Trudy Oliver: Investigating the Biology and Origins of Small Cell Lung Cancer
Published September 21, 2025
Duke Researchers Discover New Origin of Small Cell Lung Cancer in Study

View All News

Recent Publications


TMPRSS11B promotes an acidified microenvironment and immune suppression in squamous lung cancer.

Journal Article EMBO Rep · December 2025 Lung cancer is the leading cause of cancer-related deaths worldwide. Existing therapeutic options have limited efficacy, particularly for lung squamous cell carcinoma (LUSC), underscoring the critical need for the identification of new therapeutic targets. ... Full text Link to item Cite

Supplemental methods, supplemental tables 1-4, and supplemental figures 1-14 from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation

Other · November 27, 2025 <p>Table S1. The list of the SCLC cell lines (N=52) used in this study. Table S2. The list of 384 genes that constitute the NEUROD1 gene signature. Table S3. The siRNA screen results in H446 and COR-L279 cells. Table S4. Sensitivity (IC50) of ... Full text Cite

Supplementary tables 5-17 - Data tables generated during RNA-seq and ChIP-seq analysis, and the information on the siRNA screens. from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation

Other · November 27, 2025 <p>Table S5. The list of genes significantly altered in H446 cells after NEUROD1 KO. Table S6. The list of NEUROD1 peaks identified in H446 control cells (control gRNA, cl.10) Table S7. The list of NEUROD1 target genes identified by BETA. Tab ... Full text Cite
View All Publications

Recent Grants


Pharmacological Sciences Training Program

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030

Duke Research Training Program in Surgical Oncology

Inst. Training Prgm or CMEMentor · Awarded by National Cancer Institute · 2024 - 2029

NEUROD1 function in SCLC fate and plasticity

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2029

View All Grants

Education, Training & Certifications


Duke University · 2005 Ph.D.
Oklahoma Baptist University · 2001 B.S.

External Links


Oliver Lab website